This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
News|Articles|April 9, 2008
WellPoint NextRx pilots over-the-counter medication program with Blue Cross & Blue Shield of Rhode Island
WellPoint Next Rx pilots OTC generic program with Blue Cross & Blue Shield of Rhode Island to help offset out-of-pocket costs for members.
Advertisement
Advertisement
Related to this article
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
Advertisement
Advertisement
Trending on Drug Topics
1
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
2
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
3
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
4
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
5